Open AccessRevisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial
Author(s) -
Matthew B. Laurens,
Randy G. Mungwira,
Nginache Nampota,
Osward M. Nyirenda,
Titus Divala,
Maxwell Kanjala,
Felix A. Mkandawire,
Lufina Tsirizani Galileya,
Wongani Nyangulu,
Edson Mwinjiwa,
Matthew Downs,
Amy Tillman,
Terrie E. Taylor,
Jane Mallewa,
Christopher V. Plowe,
Joep J. van Oosterhout,
Miriam K. Laufer
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab252
Subject(s) - medicine , discontinuation , clinical endpoint , randomized controlled trial , population , pediatrics , environmental health
Daily co-trimoxazole is recommended for African adults living with human immunodeficiency virus (HIV) irrespective of antiretroviral treatment, immune status, or disease stage. Benefits of continued prophylaxis and whether co-trimoxazole can be stopped following immune reconstitution are unknown.